Leveraging Mutation & Methylation-Based ctDNA Profiling to Capture Tumor Heterogeneity & Enhance Clinical Readouts
5:15 pm - Wednesday 4th February 2026
- Demonstrating how broader ctDNA panels extend beyond single-gene tracking in advanced cancer, as a surrogate readout of clinical efficacy and to reveal tumor heterogeneity and evolving drivers of resistance
- Lessons from applying methylation-based sequencing approaches in oncology trials, including challenges in data interpretation and reporting
- Opportunities and limitations of integrating fragmentomics insights derived from methylation data to complement response monitoring in advanced disease
